Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

ALKS 72.80 +1.33 (1.86%)
price chart
Insider Transaction Update: Alkermes plc President Sells Company Shares
Alkermes plc (NASDAQ:ALKS), Cooke Shane, President, Alkermes plc of Alkermes PLC, unloaded 18,000 shares at an average price of $74.29 on February 23, 2015.
Volatile Stocks: Omega Healthcare Investors Inc , Alkermes Plc , Vector ...  Winston View
Volatile Stocks in List: Amgen Inc. (NASDAQ:AMGN), Alkermes plc (NASDAQ ...  eMarketsDaily
Zacks Reaffirms "Neutral" Rating for Alkermes Plc (ALKS)
Alkermes Plc logo Zacks restated their neutral rating on shares of Alkermes Plc (NASDAQ:ALKS) in a report issued on Thursday.
Share Price of Alkermes plc Drops by -4.08%  Ashburn Daily
Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of ...  Business Wire (press release)
Citigroup Inc. Lowers Alkermes Plc Price Target to $83.00 (ALKS)
Alkermes Plc logo Stock analysts at Citigroup Inc. reduced their price objective on shares of Alkermes Plc (NASDAQ:ALKS) from $85.00 to $83.00 in a report issued on Wednesday.
Why Worthington Industries (WOR), Melco Crown Entertainment (MPEL) and ...
alkermes alks stock 185 Why Worthington Industries (WOR), Melco Crown Entertainment (MPEL Not every stock out there was a winner on Tuesday, however.
Alkermes plc (ALKS) Phase 1 Study of ALKS 7106 Fails, Further Development ...
Alkermes plc (NASDAQ: ALKS) today announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule intended for the treatment of pain.
Bank of America Analysts Give Alkermes Plc a $45.00 Price Target (ALKS)
Alkermes Plc logo Bank of America set a $45.00 price objective on Alkermes Plc (NASDAQ:ALKS) in a research report released on Wednesday morning.
Alkermes Plc's Overweight Rating Reaffirmed at JPMorgan Chase & Co. (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS)'s stock had its �overweight� rating reaffirmed by equities researchers at JPMorgan Chase & Co.
Alkermes Plc Receives "Neutral" Rating from Zacks (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS)'s stock had its �neutral� rating reiterated by Zacks in a note issued to investors on Thursday.
Citigroup Inc. Trims Alkermes Plc Target Price to $83.00 (ALKS)
Alkermes Plc (NASDAQ:ALKS) had its price target reduced by Citigroup Inc. from $85.00 to $83.00 in a research report sent to investors on Wednesday morning.
Alkermes plc (ALKS) Reports Positive Topline Results From Phase 1 Study of ...
Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS).
Uptrend Stocks: Wright Medical Group Inc. (NASDAQ:WMGI), Alkermes plc ...  eMarketsDaily
Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS ...  MarketWatch